Status:
COMPLETED
Description of Patients With Type 1 Diabetes Treated With Teplizumab
Lead Sponsor:
Sanofi
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
Brief Summary
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of...
Eligibility Criteria
Inclusion
- Patient informed consent or assent (for patients \< 18 years old) according to local regulations or appropriate informed consent waivers prior to any study related activity.
- Patient received ≥ 1 day of teplizumab treatment.
Exclusion
- Participation in an interventional clinical study on the index date. Participation in an interventional clinical study is defined as initiating the product/procedure or control under investigation. An interventional clinical study is a study that requires deviation from standard clinical practice by following a study protocol.
Key Trial Info
Start Date :
February 11 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 5 2025
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT06892002
Start Date
February 11 2025
End Date
August 5 2025
Last Update
August 15 2025
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Arkansas Children's Hospital Research Institute
Little Rock, Arkansas, United States, 72202
2
University of California, San Francisco
San Francisco, California, United States, 94158
3
Barbara Davis Center For Childhood Diabetes
Aurora, Colorado, United States, 80045
4
Children's National Medical Center
Washington D.C., District of Columbia, United States, 20010